MindMaze Therapeutics: Consolidating a Global Approach to Reimbursement for Next-Generation Therapeutics 
Orion publishes Half-Year Financial Report for January–June 2023 on Monday 17 July 2023
ORION CORPORATION PRESS RELEASE 4 July 2023 at 12.00 EEST Orion publishes Half-Year Financial Report for January–June 2023 on Monday...
IBT announces outcome of its rights issue
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES...
Management in Vistin Pharma ASA purchases shares
4 July 2023: Vistin Pharma ASA (the “Company”) has on 4 July 2023 sold shares to members of its management...
Vistin Pharma ASA: Results of offer to buy back shares
4 July 2023: Reference is made to the stock exchange release of Vistin Pharma ASA (“Vistin” or the "Company") dated...
Trinity Biotech plc to Announce First Quarter Fiscal Year 2023 Financial Results
Conference Call Scheduled for July 6, 2023 at 11:00 am EASTERNDUBLIN, July 03, 2023 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq:...
Integra LifeSciences to Host Second Quarter 2023 Financial Results Conference Call on July 27, 2023
PRINCETON, N.J., July 03, 2023 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will...
Vision Sensing Acquisition Corp. Announces Payment of Fee to Extend Period to Consummate Initial Business Combination to August 3, 2023
MIAMI, July 03, 2023 (GLOBE NEWSWIRE) -- Vision Sensing Acquisition Corp. (NASDAQ: VSACU, VSAC, VSACW) (the “Company”) a special purpose...
Timber Pharmaceuticals Discloses Communication From NYSE American
WARREN, NJ, July 03, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American:...
Acutus Medical Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CARLSBAD, Calif., July 03, 2023 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB), an arrhythmia management...
IGM Announces Closing of Upsized Public Offering and Concurrent Private Placement and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
MOUNTAIN VIEW, Calif., July 03, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ: IGMS) today announced the closing of its...
Virbac reassesses its 2023 growth and Adjusted EBIT1 forecasts
Several elements are currently impacting our business and leading us today to revise our forecasts for the 2023 financial year....
MONTHLY PUBLICATION OF THE NUMBER OF SHARES COMPOSING THE SHARE CAPITAL AND OF THE TOTAL NUMBER OF VOTING RIGHTS
Nicox SA Société anonyme with a registered capital of € 50,170,498 Head Office: DRAKKAR D 2405 route des Dolines 06560 Valbonne Sophia-Antipolis R.C.S....
Additional Infant Bacterial Therapeutics product receives FDA orphan drug designation
The FDA has granted orphan drug designation for IBT’s product IBP-1016 for gastroschisis. Infants suffering from gastroschisis suffer from risks...
Abeona Therapeutics Announces $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
CLEVELAND, July 03, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that it has raised $25 million...
eureKARE seeks disruptive synthetic biology solutions to tackle environmental and sustainability challenges
The 2nd edition of the eurekAWARDS is launched! Luxembourg, Belgium, Monaco, and Paris, France – 3 July 2023: eureKARE, a pioneering company...
Coherus Launches YUSIMRY™, a Biosimilar of Humira®, at $995 per Carton in U.S.
YUSIMRY™ (adalimumab-aqvh) product image YUSIMRY™ (adalimumab-aqvh) - list price $995 per carton of two 40 mg/0.8 mL autoinjectorsSee https://www.yusimry.com for...
Zymeworks Announces Participation in Upcoming Investor Conference
VANCOUVER, British Columbia, July 03, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional...
Nevakar Injectables Announces FDA Approval of Cyclophosphamide RTD Solution
-- Ready-to-dilute, multi-dose vials reduce compounding time and waste -- BRIDGEWATER, N.J., July 03, 2023 (GLOBE NEWSWIRE) -- Nevakar Injectables...
Journey Medical Corporation Expects Topline Results from the Phase 3 Clinical Trials (MVOR-1 and MVOR-2) Evaluating DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) for the Treatment of Papulopustular Rosacea to be Announced Week of July 10, 2023
SCOTTSDALE, Ariz., July 03, 2023 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”), a commercial-stage pharmaceutical company that...
NorthX Biologics, a leading Nordic development and manufacturing organisation announces acquisition of a biologics manufacturing unit from Valneva
MATFORS, Sweden, July 03, 2023 (GLOBE NEWSWIRE) -- NorthX Biologics (‘NorthX’), a leading Nordic development and manufacturing organisation with a...